Literature DB >> 10648765

Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage.

H C O'Donnell1, J Rosand, K A Knudsen, K L Furie, A Z Segal, R I Chiu, D Ikeda, S M Greenberg.   

Abstract

BACKGROUND: Recurrent lobar intracerebral hemorrhage is the hallmark of cerebral amyloid angiopathy. The factors that predispose patients to early recurrence of lobar hemorrhage are unknown. One candidate is the apolipoprotein E gene, since both the epsilon2 and the epsilon4 alleles of apolipoprotein E appear to be associated with the severity of amyloid angiopathy.
METHODS: We performed a prospective, longitudinal study of consecutive elderly patients who survived a lobar intracerebral hemorrhage. The patients were followed for recurrent hemorrhagic stroke by interviews at six-month intervals and reviews of medical records and computed tomographic scans.
RESULTS: Nineteen of 71 enrolled patients had recurrent hemorrhages during a mean follow-up period of 23.9+/-14.8 months, yielding a 2-year cumulative rate of recurrence of 21 percent. The apolipoprotein E genotype was significantly associated with the risk of recurrence. Carriers of the epsilon2 or epsilon4 allele had a two-year rate of recurrence of 28 percent, as compared with only 10 percent for patients with the common apolipoprotein E epsilon3/epsilon3 genotype (risk ratio, 3.8; 95 percent confidence interval, 1.2 to 11.6; P=0.01). Early recurrence occurred in eight patients, four of whom had the uncommon epsilon2/epsilon4 genotype. Also at increased risk for recurrence were patients with a history of hemorrhagic stroke before entry into the study (two-year recurrence, 61 percent; risk ratio, 6.4; 95 percent confidence interval, 2.2 to 18.5; P<0.001).
CONCLUSIONS: The apolipoprotein E genotype can identify patients with lobar intracerebral hemorrhage who are at highest risk for early recurrence. This finding makes possible both the provision of prognostic information to patients with lobar hemorrhage and a method of targeting and assessing potential strategies for prevention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648765     DOI: 10.1056/NEJM200001273420403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  120 in total

Review 1.  Science, medicine, and the future. Genetic epidemiology.

Authors:  J Kaprio
Journal:  BMJ       Date:  2000-05-06

2.  Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy.

Authors:  R Christie; M Yamada; M Moskowitz; B Hyman
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  Apolipoprotein E epsilon 2 is associated with new hemorrhage risk in brain arteriovenous malformations.

Authors:  Ludmila Pawlikowska; K Y Trudy Poon; Achal S Achrol; Charles E McCulloch; Connie Ha; Kristen Lum; Jonathan G Zaroff; Nerissa U Ko; S Claiborne Johnston; Stephen Sidney; Douglas A Marchuk; Michael T Lawton; Pui-Yan Kwok; William L Young
Journal:  Neurosurgery       Date:  2006-05       Impact factor: 4.654

Review 4.  [Zerebrale Amyloidangiopathie : Cerebral amyloid angiopathy].

Authors:  F Block
Journal:  Nervenarzt       Date:  2011-02       Impact factor: 1.214

5.  The characteristics of superficial siderosis and convexity subarachnoid hemorrhage and clinical relevance in suspected cerebral amyloid angiopathy.

Authors:  Jun Ni; Eitan Auriel; Jenelle Jindal; Alison Ayres; Kristin M Schwab; Sergi Martinez-Ramirez; Edip M Gurol; Steven M Greenberg; Anand Viswanathan
Journal:  Cerebrovasc Dis       Date:  2015-04-08       Impact factor: 2.762

6.  Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage.

Authors:  Michael Moussouttas
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

7.  TOMM40 in Cerebral Amyloid Angiopathy Related Intracerebral Hemorrhage: Comparative Genetic Analysis with Alzheimer's Disease.

Authors:  Valerie Valant; Brendan T Keenan; Christopher D Anderson; Joshua M Shulman; William J Devan; Alison M Ayres; Kristin Schwab; Joshua N Goldstein; Anand Viswanathan; Steven M Greenberg; David A Bennett; Philip L De Jager; Jonathan Rosand; Alessandro Biffi
Journal:  Transl Stroke Res       Date:  2012-04-12       Impact factor: 6.829

Review 8.  [Cerebral amyloid angiopathy and dementia].

Authors:  P Berlit; K Keyvani; M Krämer; R Weber
Journal:  Nervenarzt       Date:  2015-10       Impact factor: 1.214

9.  Impaired visual evoked flow velocity response in cerebral amyloid angiopathy.

Authors:  E E Smith; M Vijayappa; F Lima; P Delgado; L Wendell; J Rosand; S M Greenberg
Journal:  Neurology       Date:  2008-10-28       Impact factor: 9.910

Review 10.  Antithrombotic therapy for the treatment of atrial fibrillation in the elderly.

Authors:  Margaret C Fang
Journal:  J Interv Card Electrophysiol       Date:  2009-01-16       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.